Reltone 400 Mg
Payments companies reported to CMS as associated with Reltone 400 Mg. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Reltone 400 Mg, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Reltone 400 Mg
These are the largest totals companies reported as associated with Reltone 400 Mg. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Loic Tchokouani | New York, NY | Surgery | $37,497.58 |
| Jason Roy | Orlando, FL | Nurse Practitioner | $36,047.45 |
| Philip Rabito | New York, NY | $26,495.46 | |
| Brian Berberian | Bangor, ME | Gastroenterology (Internal Medicine) | $17,082.99 |
| Ronnie Fass | Cleveland, OH | Gastroenterology (Internal Medicine) | $14,000.00 |
| Vishwanath Danthuluri | Atlanta, GA | Surgery | $11,909.34 |
| Suhel Ahmed | Hackensack, NJ | Internal Medicine | $11,379.71 |
| Kostas Sideridis | Syosset, NY | Gastroenterology (Internal Medicine) | $10,225.64 |
| Theofanis Mitsinikos | Stony Brook, NY | Endocrinology, Diabetes & Metabolism | $8,944.33 |
| Rotem Amir | Hallandale Beach, FL | Internal Medicine | $8,534.19 |
Prescribed Reltone 400 Mg?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.